(Date:12/11/2009)... 11 Dendreon Corporation (Nasdaq: DNDN ... previously announced public offering have exercised in full ... of common stock at the public offering price ... the option increases the size of the offering ... stock. Dendreon expects to receive net proceeds ...
(Date:12/11/2009)... DIEGO, Dec. 11 Ambit Biosciences Corporation announced ... Texas M. D. Anderson Cancer Center of the first ... Monotherapy E fficacy) Phase 2 pivotal ... leukemia (AML). AC220 is a novel, orally available, ... designed as a FMS-like tyrosine kinase-3 (FLT3) inhibitor. ...
(Date:12/11/2009)... 11 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ: ... the appointment of Dr. Alan Warrander to the ... Business Development. ,, "Dr. Warrander will be responsible ... for REOLYSIN(R)," said Dr. Brad Thompson, President and ... the design of a Phase 3 trial examining ...
(Date:12/10/2009)... Endologix, Inc. (Nasdaq: ELGX ), ... announced today that Dan Lemaitre, former President and ... of Directors effective December 11, 2009. Endologix ... directors. ,, Franklin D. Brown, Chairman of the ... Lemaitre to the Endologix Board of Directors. ...
Breaking Biology Technology:Dendreon Announces Exercise of Option by Underwriters in its Common Stock Offering 2Dendreon Announces Exercise of Option by Underwriters in its Common Stock Offering 3Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 2Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 3Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 4Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 5Oncolytics Biotech(R) Inc. Appoints Senior Vice President, Global Licensing and Business Development 2Oncolytics Biotech(R) Inc. Appoints Senior Vice President, Global Licensing and Business Development 3Endologix Appoints Dan Lemaitre to its Board of Directors 2... treats cancer, patients quickly and effectively ... Mich., Oct. 30 Beaumont Hospital, Royal Oak,(Royal ... using the new,Elekta Axesse(TM), the ultimate whole-body cancer ... and therapeutic efficacy in,stereotactic radiation therapy, which involves ...
... Reduces Bacteria to Levels below Detection; Can ... Permanent Protection in Everyday Products, HAMPTON, N.H., Oct. ... embed a natural balance of silver and copper,into fiber, ... percent effective in killing methicillin-resistant Staphylococcus,aureus (MRSA) bacteria to ...
... Broaden Offerings in the Pharmaceutical Value Chain, ... ShangPharma Corporation,("ShangPharma" or the "Group"), a leading ... company, today announced,that leading global private investment ... TPG Biotech Fund (collectively known as "TPG"), ...
Other Biology Technology:Beaumont Hospital, Royal Oak Treats Its First Patients With Elekta Axesse 2Beaumont Hospital, Royal Oak Treats Its First Patients With Elekta Axesse 3Beaumont Hospital, Royal Oak Treats Its First Patients With Elekta Axesse 4Innovative Fosshield(R) Antimicrobial Technology Shown to Continuously Kill MRSA 'Superbug' 2Innovative Fosshield(R) Antimicrobial Technology Shown to Continuously Kill MRSA 'Superbug' 3Innovative Fosshield(R) Antimicrobial Technology Shown to Continuously Kill MRSA 'Superbug' 4Innovative Fosshield(R) Antimicrobial Technology Shown to Continuously Kill MRSA 'Superbug' 5ShangPharma Receives Strategic Investment from TPG 2ShangPharma Receives Strategic Investment from TPG 3ShangPharma Receives Strategic Investment from TPG 4Request Info...
Tight junctions are complexes of proteins that create intercellular boundaries between the plasma membrane domains of epithelial and endothelial cells. Antigen: Synthetic peptide corresponding to...
Myeloid Marker (BM-1)...
Form: Concentrated Applications: ELISA...
Biology Products:Biology NavigationMedical Navigation